BioPharmSignal logoBioPharmSignal

Biotech News

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid (PYPD)PolyPidClinical readout

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.

Related news

PYPDPolyPid2026-04-13 13:15 EST

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PYPDPolyPid2025-12-03 13:30 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

PYPDPolyPid2026-08-12 11:30 EST

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PYPDPolyPid2026-07-29 12:30 EST

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PYPDPolyPid2026-07-21 11:30 EST

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Stock data

Close
5.10 USD
Market cap
93.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States